Cognition in (pre)symptomatic Dutch-type hereditary and sporadic cerebral amyloid angiopathy.
Dutch‐type hereditary cerebral amyloid angiopathy
cerebral amyloid angiopathy
cerebral small vessel disease burden
cognitive dysfunction
hereditary cerebral amyloid angiopathy
intracerebral hemorrhage
magnetic resonance imaging
presymptomatic mutation carriers
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
revised:
20
06
2024
received:
09
01
2024
accepted:
14
07
2024
medline:
10
10
2024
pubmed:
10
10
2024
entrez:
10
10
2024
Statut:
aheadofprint
Résumé
Cerebral amyloid angiopathy (CAA) is a main cause of cognitive dysfunction in the elderly. We investigated specific cognitive profiles, cognitive function in the stage before intracerebral hemorrhage (ICH), and the association between magnetic resonance imaging (MRI) based cerebral small vessel disease (cSVD) burden in CAA because data on these topics are limited. We included Dutch-type hereditary CAA (D-CAA) mutation carriers with and without ICH, patients with sporadic CAA (sCAA), and age-matched controls. Cognition was measured with a standardized test battery. Linear regression was performed to assess the association between MRI-cSVD burden and cognition. D-CAA ICH- mutation carriers exhibited poorer global cognition and executive function compared to age-matched controls. Patients with sCAA performed worse across all cognitive domains compared to D-CAA ICH+ mutation carriers and age-matched controls. MRI-cSVD burden is associated with decreased processing speed. CAA is associated with dysfunction in multiple cognitive domains, even before ICH, with increased MRI-cSVD burden being associated with slower processing speed. Cognitive dysfunction is present in early disease stages of cerebral amyloid angiopathy (CAA) before the occurrence of symptomatic intracerebral hemorrhage (sICH). Presymptomatic Dutch-type CAA (D-CAA) mutation carriers show worse cognition than age-matched controls. More early awareness of cognitive dysfunction in CAA before first sICH is needed. Increased cerebral small vessel disease CAA-burden on magnetic resonance imaging is linked to a decrease in processing speed.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : TRACK D-CAA consortium
Organisme : Dutch CAA foundation
Organisme : Vereniging HCHWA-D
Informations de copyright
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Natté R, Maat‐Schieman MLC, Haan J, Bornebroek M, Roos RAC, Van Duinen SG. Dementia in hereditary cerebral hemorrhage with amyloidosis‐dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. Ann Neurol. 2001;50:765‐772.
Van Rooden S, Van Opstal AM, Labadie G, et al. Early magnetic resonance imaging and cognitive markers of hereditary cerebral amyloid angiopathy. Stroke. 2016;47(12):3041‐3044.
Wermer MJH, Greenberg SM. The growing clinical spectrum of cerebral amyloid angiopathy. Curr Opin Neurol. 2018;31(1):28‐35.
Koemans EA, Chhatwal JP, van Veluw SJ, et al. Progression of cerebral amyloid angiopathy: a pathophysiological framework. Lancet Neurol. 2023;22(7):632‐642.
Gahr M, Nowak DA, Connemann BJ, Schönfeldt‐Lecuona C. Cerebral amyloidal angiopathy—A disease with implications for neurology and psychiatry. Brain Res. 2013;1519:19‐30.
Xiong L, Davidsdottir S, Reijmer YD, et al. Cognitive profile and its association with neuroimaging markers of non‐demented cerebral amyloid angiopathy patients in a stroke unit. J Alzheimer's Dis. 2016;52(1):171‐178.
McCreary CR, Beaudin AE, Subotic A, et al. Cross‐sectional and longitudinal differences in peak skeletonized white matter mean diffusivity in cerebral amyloid angiopathy. Published online 2020. doi:10.1016/j.nicl.2020.102280
Gokcal E, Horn MJ, Van Veluw SJ, et al. Lacunes, microinfarcts, and vascular dysfunction in cerebral amyloid angiopathy. Neurology. 2021;96(12):e1646‐e1654.
Reijmer YD, Fotiadis P, Martinez‐Ramirez S, et al. Structural network alterations and neurological dysfunction in cerebral amyloid angiopathy. Brain. 2015;138(1):179‐188.
Bornebroek M, Haan J, Maat‐Schieman MLC, Van Duinen SG, Roos RAC. Hereditary cerebral hemorrhage with amyloidosis‐Dutch type (HCHWA‐D): i–A review of clinical, radiologic and genetic aspects. Brain Pathol. 1996;6(2):111‐114.
Van Broeckhoven C, Haan J, Bakker E, et al. Amyloid β protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science (1979). 1990;248(4959):1120‐1122.
Koemans EA, Voigt S, Rasing I, et al. Migraine with aura as early disease marker in hereditary dutch‐type cerebral amyloid angiopathy. Stroke. 2020;51(4):1094‐1099.
Maat‐Schieman MLC, Van Duinen SG, Bornebroek M, Haan J, Roos RAC. Hereditary cerebral hemorrhage with amyloidosis‐Dutch type (HCHWA‐D): iI—A review of histopathological aspects. Brain Pathol. 1996;6(2):115‐120.
Bornebroek M, Haan J, Roos RAC, Bornebroek' M, Haan' p2 J. Amyloid The Journal of Protein Folding Disorders Hereditary cerebral hemorrhage with amyloidosis‐Dutch type (HCHWA‐D): a review of the variety in phenotypic expression Review Hereditary cerebral hemorrhage with amyloidosis‐Dutch type (HCHWA‐D): a review of the variety in phenotypic expression. J Exp Clin Invest. 1999;6:215‐224.
Bornebroek M, Haan J, Maat‐Schieman MLC, Van Duinen SG, Roos RAC. Hereditary cerebral hemorrhage with amyloidosis‐Dutch type (HCHWA‐D): i—A review of clinical, radiologic and genetic aspects. Brain Pathol. 1996;6(2):111‐114.
Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21(8):714‐725.
Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy‐related vascular cognitive impairment. Stroke. 2004;35(11):2616‐2619. SUPPL. 1.
Folstein MF, Folstein SE, Mchugh PR. “mini‐mental state” a practical method for grading the cognitive state of patients for the clinician*. J gsychiaf Res. 1975;12:189‐198.
Nasreddine ZS, Phillips NA, Bédirian V, et al. Montreal cognitive assessment. Am J Geriatr Psychiatry. 2003.
Saan RJ, Deelman BG. (De 15‐woordentest A en B. Een voorlopige handleiding (in Dutch)). Dept Neuropsychology, UMCG; 1986.
Bouma A, Mulder J, Lindeboom J, Schmand B. Handboek neuropsychologische diagnostiek. 2nd ed.. 2012.
Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643‐662.
Reitan RM. Trail Making Test: manual for administration, scoring, and interpretation. Indianapolis: Indiana University Medical Center. 1958:134.
Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55(11):1621‐1626.
Miller GA. The magical number seven, plus or minus two: some limits on our capacity for processing information. Psychol Rev. 1956;63(2):81.
Ardila A. A cross‐linguistic comparison of category verbal fluency test (ANIMALS): a systematic review. Arch Clin Neuropsychol. 2020;35(2):218‐225.
Benedict RHB, Schretlen D, Groninger L, Brandt J. The Clinical Neuropsychologist. 1997;12(1):43‐55.
Schmand B, Groenink SC, Van Den Dungen M. Letterfluency: psychometric properties and Dutch normative data. Tijdschr Gerontol Geriatr. 2008;39(2):64‐76.
Arbuthnott K, Frank J. Trail making test, part B as a measure of executive control: validation using a set‐switching paradigm. J Clin Exp Neuropsychol. 2000;22(4):518‐528.
Centraal Bureau voor de Statistiek. Standaard Onderwijsindeling 2021 ‐ Editie 2020/'21. Centraal Bureau voor de Statistiek; 2021 14‐04‐2023.
Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822‐838. 8.
Charidimou A, Martinez‐Ramirez S, Reijmer YD, et al. Total magnetic resonance imaging burden of small vessel disease in cerebral amyloid angiopathy: an imaging‐pathologic study of concept validation. JAMA Neurol. 2016;73(8):994‐1001.
de Vent NR, van Rentergem JAA, Schmand BA, Murre JMJ, Huizenga HM. Advanced Neuropsychological Diagnostics Infrastructure (ANDI): a normative database created from control datasets. Front Psychol. 2016;7:214872. OCT.
Bouma A, Mulder J, Lindeboom J, Schmand B. Handboek neuropsychologische diagnostiek. 2 ed.. Pearson Assessment and Information B.V.; 2012.
American Psychiatric Association DSMTF. & American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM‐5. American psychiatric association; 2013.
Planton M, Raposo N, Albucher JF, Pariente J. Cerebral amyloid angiopathy‐related cognitive impairment: the search for a specific neuropsychological pattern. Rev Neurol (Paris). 2017;173(9):562‐565.
McLauchlan D, Malik GA, Robertson NP. Cerebral amyloid angiopathy: subtypes, treatment and role in cognitive impairment. J Neurol. 2017;264(10):2184‐2186.
Banerjee G, Wilson D, Ambler G, et al. Cognitive impairment before intracerebral hemorrhage is associated with cerebral amyloid angiopathy. Stroke. 2018;49(1):40‐45.
Huijts M, Duits A, Van Oostenbrugge RJ, Kroon AA, De Leeuw PW, Staals J. Accumulation of MRI markers of cerebral small vessel disease is associated with decreased cognitive function. A study in first‐ever lacunar stroke and hypertensive patients. Front Aging Neurosci. 2013;5:72. NOV.
Greenberg SM, Bacskai BJ, Hernandez‐Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30.
Jack CR Jr, Bennett DA, Blennow K, et al. NIA‐AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535‐562.
De Kort AM, Kaushik K, Kuiperij HB, et al. The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy. Alzheimers Res Ther. 2024;16(1):1‐12.